Who
Michael Weiser
Director
Company insider
Files Form 4 as: Director, Iovance Biotherapeutics; Director, Alaunos Therapeutics; Director, Emisphere Technologies; Director, Chelsea Therapeutics International; Director and Other, TG Therapeutics; Director, Hana Biosciences; Director, VioQuest Pharmaceuticals; Director, Innovive Pharmaceuticals.
In numbers
- Trades disclosed
- 151
- Buys
- 8
- Sells
- 1
- Bought
- $105K
- Sold
- $98K
- Companies
- 9
- Companies where not an officer
- 8
- First trade
- 11 Jan 2006
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,316 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,316 at $0.00 | filing |
| 13 Jun 2025filed 17 Jun 2025 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,546 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,303 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,955 at $0.00 | filing |
| 10 Jun 2022filed 14 Jun 2022 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,204 at $0.00 | filing |
| 31 May 2022filed 2 Jun 2022 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $15K2,187 at $6.79 | filing |
| 31 May 2022filed 2 Jun 2022 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $53K7,813 at $6.80 | filing |
| 29 Jun 2021filed 1 Jul 2021 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 8 Jun 2020filed 10 Jun 2020 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 10 Jun 2019filed 11 Jun 2019 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 17 Jul 2018filed 19 Jul 2018 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 15 Mar 2018filed 19 Mar 2018 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 30 Dec 2017filed 3 Jan 2018 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code F | $25K6,021 at $4.14 | filing |
| 29 Dec 2017filed 3 Jan 2018 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | —17,258 at $0.00 | filing |
| 8 Dec 2017filed 11 Dec 2017 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code M | $55K20,000 at $2.73 | filing |
| 8 Dec 2017filed 11 Dec 2017 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code F | $55K12,325 at $4.43 | filing |
| 8 Dec 2017filed 11 Dec 2017 | TCRT Alaunos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 12 Jun 2017filed 14 Jun 2017 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code M | $73K15,000 at $4.85 | filing |
News
Undercovered Stocks: Hess Midstream, Iovance Biotherapeutics, Netlist, And MoreIOVA · seekingalpha.com · 19 Oct 2026Comparing MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)IOVA · tickerreport.com · 15 Oct 2026Biotech Stock Alaunos Therapeutics (NASDAQ: TCRT) Sees Triple Digit Gains on Acquisition and FundingTCRT · investorideas.com · 13 Oct 2026Alaunos Therapeutics Announces Acquisition of Velaris TherapeuticsTCRT · manilatimes.net · 13 Oct 2026Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $11.00IOVA · themarketsdaily.com · 11 Oct 2026TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026TGTX · simcoereformer.ca · 8 Oct 2026
0 headlines in the last 90 days name Michael Weiser; 6 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.